Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study (Q82955028)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Dustin G James

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Da Hea Seo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jiajing Chen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Caroline Vemulapalli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christian D Stone

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

19 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1806-1810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21170755%20AND%20SRC:MED&resulttype=core&format=json

Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness

18 January 2020

cites work

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

1 reference

12 December 2020

Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments.

1 reference

12 December 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

12 December 2020

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

12 December 2020

Role of the LFA-1 molecule in cellular interactions required for antibody production in humans.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.

1 reference

12 December 2020

Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD

1 reference

12 December 2020

Alteration in expression of beta 2 integrins on lamina propria lymphocytes in ulcerative colitis and Crohn's disease

1 reference

12 December 2020

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

1 reference

12 December 2020